Survival of advanced melanoma patients treated with immunotherapy and targeted therapy: a real‐world study

2021 ◽  
Author(s):  
Su‐Yeon Yu ◽  
Dan Mckavanagh ◽  
Ian McPherson ◽  
Euan Walpole ◽  
Victoria Atkinson ◽  
...  
Keyword(s):  
Targeted Therapy ◽  
Real World ◽  
Advanced Melanoma ◽  
Melanoma Patients

scholarly journals 1103P Long-term survival of real-world advanced melanoma patients treated with targeted therapy

2020 ◽  
Vol 31 ◽  
pp. S745-S746
Author(s):  
R. Ismail ◽  
A. de Boer ◽  
M. van Dartel ◽  
D. Hilarius ◽  
M. van Zeijl ◽  
...  
Keyword(s):  
Targeted Therapy ◽  
Real World ◽  
Advanced Melanoma ◽  
Term Survival ◽  
Long Term Survival ◽  
Melanoma Patients

Immune gene profiling of pretreatment tumor samples in "real-world" advanced melanoma patients treated with anti-PD-1 and/or anti-CTLA-4.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. 9585-9585
Author(s):  
Elisa A. Rozeman ◽  
Marnix Heimen Geukes Foppen ◽  
SuFey Ong ◽  
Ruben Lacroix ◽  
Patrick Danaher ◽  
...  
Keyword(s):  
Real World ◽  
Advanced Melanoma ◽  
Gene Profiling ◽  
Immune Gene ◽  
Melanoma Patients

scholarly journals Experience from Turkish centers participating in the Early Access Program (EAP): Preliminary real-world safety data of nivolumab (nivo) combined with ipilimumab (ipi) in pre-treated advanced melanoma patients

2018 ◽  
Vol 4 (3) ◽  
pp. 125-129 ◽  
Author(s):  
Nuri Karadurmus ◽  
Mehmet Ali Nahit Sendur ◽  
Burcak Karaca ◽  
Omer Fatih Olmez ◽  
Ilhan Hacibekiroglu ◽  
...  
Keyword(s):  
Real World ◽  
Safety Data ◽  
Advanced Melanoma ◽  
Early Access ◽  
Melanoma Patients ◽  
Access Program

Combined BRAF-Targeted Therapy with Immunotherapy in BRAF-Mutated Advanced Melanoma Patients

2021 ◽  
Vol 23 (12) ◽  
Author(s):  
Pier Francesco Ferrucci ◽  
Marko Lens ◽  
Emilia Cocorocchio
Keyword(s):  
Targeted Therapy ◽  
Advanced Melanoma ◽  
Melanoma Patients

Treatment of BRAF-mutated metastatic melanoma patients with targeted therapy combinations or immunotherapy in real world setting.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. e21630-e21630
Author(s):  
Janja Ocvirk ◽  
Marija Ignjatovic ◽  
Martina Rebersek ◽  
Marko Boc
Keyword(s):  
Targeted Therapy ◽  
Metastatic Melanoma ◽  
Real World ◽  
Real World Setting ◽  
Melanoma Patients

scholarly journals Switching to Immune Checkpoint Inhibitors upon Response to Targeted Therapy; The Road to Long-Term Survival in Advanced Melanoma Patients with Highly Elevated Serum LDH?

Cancers ◽  
2019 ◽  
Vol 11 (12) ◽  
pp. 1940 ◽  
Author(s):  
Maartje G. Schouwenburg ◽  
Karijn P.M. Suijkerbuijk ◽  
Rutger H.T. Koornstra ◽  
Anouk Jochems ◽  
Michiel C.T. van Zeijl ◽  
...  
Keyword(s):  
Targeted Therapy ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Elevated Serum ◽  
Subsequent Treatment ◽  
Advanced Melanoma ◽  
Term Survival ◽  
Melanoma Patients

The prognosis of patients with advanced melanoma has improved dramatically. However, the clinical outcomes of patients with highly elevated serum lactate dehydrogenase (LDH) remain very poor. The aim of this study was to explore whether patients with normalized LDH after targeted therapy could benefit from subsequent treatment with immune checkpoint inhibitors (ICI). Data from all patients with BRAF-mutant metastatic melanoma with a highly elevated serum LDH at baseline (≥2× upper limit of normal) receiving first-line targeted therapy between 2012 and 2019 in the Netherlands were collected. Patients were stratified according to response status to targeted therapy and change in LDH at start of subsequent treatment with ICI. Differences in overall survival (OS) between the subgroups were compared using log-rank tests. After a median follow-up of 35.1 months, median OS of the total study population (n = 360) was 4.9 months (95% CI 4.4–5.4). Of all patients receiving subsequent treatment with ICI (n = 113), survival from start of subsequent treatment was significantly longer in patients who had normalized LDH and were still responding to targeted therapy compared to those with LDH that remained elevated (median OS 24.7 vs. 1.1 months). Our study suggests that introducing ICI upon response to targeted therapy with normalization of LDH could be an effective strategy in obtaining long-term survival in advanced melanoma patients with initial highly elevated serum LDH.

scholarly journals Real‐world outcomes of advanced melanoma patients not represented in phase III trials

2020 ◽  
Vol 147 (12) ◽  
pp. 3461-3470
Author(s):  
Michiel C. T. Zeijl ◽  
Rawa K. Ismail ◽  
Liesbeth C. Wreede ◽  
Alfonsus J. M. Eertwegh ◽  
Anthonius Boer ◽  
...  
Keyword(s):  
Real World ◽  
Advanced Melanoma ◽  
Phase Iii ◽  
Phase Iii Trials ◽  
Melanoma Patients

scholarly journals Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland

2017 ◽  
Vol 27 (4) ◽  
pp. 358-368 ◽  
Author(s):  
Joanna Mangana ◽  
Phil F. Cheng ◽  
Corina Kaufmann ◽  
Valerie C. Amann ◽  
Anna L. Frauchiger ◽  
...  
Keyword(s):  
Targeted Therapy ◽  
Life Experience ◽  
Checkpoint Inhibitors ◽  
Real Life ◽  
Advanced Melanoma ◽  
Melanoma Patients
Sign in / Sign up

Export Citation Format

Share Document